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New therapeutic strategies are needed to combat the tuberculosis pandemic and the
spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of
the disease, which remain a serious public health challenge worldwide1, 2. The most
urgent clinical need is to discover potent agents capable of reducing the duration of
MDR and XDR tuberculosis therapy with a success rate comparable to that of current
therapies for drug-susceptible tuberculosis. The last decade has seen the discovery of
new agent classes for the management of tuberculosis3, 4, 5, several of which are
currently in clinical trials6, 7, 8. However, given the high attrition rate of drug
candidates during clinical development and the emergence of drug resistance, the
discovery of additional clinical candidates is clearly needed. Here, we report on a
promising class of imidazopyridine amide (IPA) compounds that block Mycobacterium
tuberculosis growth by targeting the respiratory cytochrome bc1 complex. The
optimized IPA compound Q203 inhibited the growth of MDR and XDR M. tuberculosis
clinical isolates in culture broth medium in the low nanomolar range and was
efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body
weight, which highlights the potency of this compound. In addition, Q203 displays
pharmacokinetic and safety profiles compatible with once-daily dosing. Together, our
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